Yama F Mujadidi
BCA Computer Application , MSc in Information Technology and Software Engineering
Clinical Trials IT and Development Lead
Yama F Mujadidi has expertise in the design and development of software and is currently working with Oxford Vaccine Group in the capacity of Clinical Trials IT and Development Lead. He acquired an MSc in Information Technology from University of Bradford United Kingdom, in 2012 after he earned a First class degree in BCA Computer Application from the University of Pune, in the year 2010.
Yama joined Oxford Vaccine Group in June 2013 and tasked to provide specialist advice to research groups to improve quality of clinical trials and to develop an application based on the vaccine knowledge project for use in smart-phones/tablets. Before Oxford Vaccine Group, He had been working with Omni Communication Product Limited as a software developer and contributed to the development of a multi-communication application for use in smartphones and tablets.
Recent publications
-
Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) - a protocol for two parallel, open-label, randomised controlled trials.
Journal article
Kelly S. et al, (2023), Trials, 24
-
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Journal article
Liu X. et al, (2023), J Infect, 87, 18 - 26
-
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Journal article
Kelly E. et al, (2023), J Infect
-
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Journal article
Shaw RH. et al, (2023), J Infect, 86, 574 - 583
-
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
Journal article
Liu X. et al, (2023), J Infect, 86, 540 - 541
-
Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.
Journal article
Khanam F. et al, (2023), Vaccine
-
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Journal article
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209
-
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
Journal article
EWER K., (2023), Clinical and Experimental Immunology
-
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Journal article
Shaw RH. et al, (2022), Lancet Respir Med, 10, 1049 - 1060
-
Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study.
Journal article
Shrestha S. et al, (2022), Lancet Glob Health, 10, e1494 - e1504
-
Successful integration of newborn genetic testing into UK routine screening using prospective consent to determine eligibility for clinical trials.
Journal article
Bendor-Samuel OM. et al, (2022), Arch Dis Child
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Journal article
Li G. et al, (2022), Lancet, 399, 2212 - 2225
-
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Journal article
Munro APS. et al, (2022), Lancet Infect Dis
-
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
Journal article
Ogbe A. et al, (2022), JCI Insight, 7
-
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial.
Journal article
Liu X. et al, (2022), J Infect
-
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Journal article
Stuart ASV. et al, (2022), Lancet, 399, 36 - 49
-
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Journal article
Lazarus R. et al, (2021), Lancet, 398, 2277 - 2287
-
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Journal article
Munro APS. et al, (2021), Lancet
-
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Journal article
Clemens SAC. et al, (2021), Nature Communications, 12
-
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Journal article
Feng S. et al, (2021), Nat Med, 27, 2032 - 2040
-
Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.
Journal article
Shakya M. et al, (2021), Lancet Glob Health, 9, e1561 - e1568
-
Corrigendum to: Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial.
Journal article
Theiss-Nyland K. et al, (2021), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73, 1950 - 1950
-
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
Journal article
Clemens SAC. et al, (2021), Nat Commun, 12
-
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire.
Journal article
Swanson PA. et al, (2021), Science translational medicine, eabj7211 - eabj7211
-
Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses
Preprint
Ogbe A. et al, (2021)
-
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Journal article
Liu X. et al, (2021), Lancet, 398, 856 - 869
-
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
EWER K. et al, (2021), The Lancet
-
Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
Journal article
Qadri F. et al, (2021), Lancet, 398, 675 - 684
-
T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.
Journal article
Swanson PA. et al, (2021), medRxiv
-
Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine
Journal article
Liu X. et al, (2021), SSRN Electronic Journal